We propose to establish a Program in Cancer Outcomes Research Training (PCORT) within the Dana-Farber/Harvard Cancer Center (DF/HCC). The Program will be curriculum-based, highly interdisciplinary and involve collaboration across the entire Cancer Center and affiliated institutions. The goal of the Program will be to train pre- and post-doctoral candidates who will become leaders in cancer outcomes research. We request funding to support 4 M.D. and/or Ph.D. trainees and 2 pre-doctoral trainees per year, all of whom will spend at least two years in the Program. We will seek to recruit individuals with diverse prior research experience and training, and will integrate all trainees into a highly collaborative research environment. We will also actively recruit highly qualified minority and women applicants to the program. The Program will involve 3 components: 1) a specialized curriculum; 2) other didactic experiences; and 3) mentored, multidisciplinary cancer-related outcomes research. The specialized curriculum will involve weekly seminars alternating between didactic lectures and """"""""research-in-progress"""""""" presentations by trainees and faculty. Appropriately qualified trainees will also attend the Harvard Program in Clinical Effectiveness, an intensive, seven-week, 15 credit classroom-based program which includes required courses in epidemiology and biostatistics, as well as a variety of electives. Qualified trainees may continue to take courses at HSPH, leading to a Master?s degree. Trainees will also be permitted to attend additional courses throughout Harvard University and its affiliated schools. Trainees will spend the largest part of their time participating in mentored cancer outcomes research under the direct supervision of PCORT faculty. All research projects undertaken by trainees will be multidisciplinary and highly collaborative. Trainees will be exposed to a broad range of cancer outcomes research. Trainees will be evaluated throughout and upon completion of the Program. After successful completion of the training program, they will be well prepared to conduct independent, externally funded, cancer outcomes research, and to do so effectively as part of a multidisciplinary research team.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
1R25CA092203-01A1
Application #
6473127
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2002-09-01
Project End
2007-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$361,779
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Melamed, Alexander; Fink, Günther; Wright, Alexi A et al. (2018) Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 360:j5463
Brown, Justin C; Caan, Bette J; Meyerhardt, Jeffrey A et al. (2018) The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS). J Cachexia Sarcopenia Muscle 9:664-672
Melamed, Alexander; Margul, Daniel J; Chen, Ling et al. (2018) Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med 379:1905-1914
Merker, Vanessa L; Dai, Annie; Radtke, Heather B et al. (2018) Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res 18:668
Hinchcliff, Emily; Melamed, Alexander; Bregar, Amy et al. (2018) Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Gynecol Oncol 148:168-173
Friedrich, Paola; Guerra-García, Pilar; Stetson, Alyssa et al. (2018) Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:96-102
Mehtsun, Winta T; Zheng, Jie; Orav, E John et al. (2017) Unintended Consequences of the 30-Day Mortality Metric: Fact or Fiction. Ann Surg 266:962-967
Bregar, Amy J; Alejandro Rauh-Hain, J; Spencer, Ryan et al. (2017) Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis. Gynecol Oncol 145:114-121
Brown, Justin C; Harhay, Michael O; Harhay, Meera N (2017) Nonalcoholic fatty liver disease and mortality among cancer survivors. Cancer Epidemiol 48:104-109
Odejide, Oreofe O; Cronin, Angel M; Earle, Craig C et al. (2017) Why are patients with blood cancers more likely to die without hospice? Cancer 123:3377-3384

Showing the most recent 10 out of 121 publications